Logans Dental

The Best In Health

Vallon Pharmaceuticals Announces Review of Strategic Alternatives

3 min read
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
Vallon Pharmaceuticals Announces Review of Strategic Alternatives

Vallon Pharmaceuticals Inc.

Philadelphia, PA, April 22, 2022 (World NEWSWIRE) — Vallon Prescribed drugs, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a scientific-stage biopharmaceutical company principally centered on the enhancement of novel medicine that are designed to prevent abuse in the cure of CNS issues, these days declared it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to appraise strategic choices for the Business with the intention of maximizing shareholder price.

Ladenburg has been engaged to suggest Vallon on the strategic assessment procedure, which could include things like, with no limitation, exploring the prospective for a doable merger, business combination, expense into the Organization, or a buy, license or other acquisition of belongings. This approach might not result in any transaction and the Company does not intend to disclose more details until and until eventually it has entered into a specific transaction. Thompson Hine LLP serves as Vallon’s lawful counsel and will assist with the exploration of options.

The Business is continuing to evaluate the greatest route ahead for ADAIR, its novel abuse-deterrent formulation of amphetamine for the treatment method of notice deficit hyperactivity condition (ADHD) and narcolepsy, and for ADMIR, its novel abuse-deterrent formulation of methylphenidate (Ritalin). In the meantime, and in conjunction with the exploration of strategic alternate options, the Company is streamlining its functions in order to maintain its funds and hard cash methods.

About Vallon Prescribed drugs, Inc.

Vallon Pharmaceuticals, Inc. is a scientific-stage biopharmaceutical enterprise, headquartered in Philadelphia, PA. The Corporation is targeted on the growth of new prescription drugs to support patients with CNS issues. The Company’s direct investigational merchandise prospect, ADAIR, is a novel abuse-deterrent formulation of amphetamine immediate release staying produced for the procedure of ADHD and narcolepsy.

For much more details about the firm, you should pay a visit to www.vallon-pharma.com or hook up with us on LinkedIn or Twitter.

References and backlinks to internet sites have been supplied for comfort, and the information contained on any this kind of site is not a section of, or included by reference into, this press release. Vallon is not responsible for the contents of 3rd-social gathering internet sites.

Forward Seeking Statements

This push release incorporates “forward-wanting statements” that are primarily based on Vallon’s present anticipations and matter to inherent uncertainties, threats and assumptions that are tricky to forecast, including, devoid of limitation, Vallon’s skill to execute its business enterprise approach, proceed its advancement and fund its ongoing enterprise routines as planned, Vallon’s expectations with regard to its strategic review approach and any opportunity strategic transactions, Vallon’s potential to establish and commercialize its solution candidates, Vallon’s anticipations associated to final results of medical trials and experiments, Vallon’s expectations with regard to the analysis of data and outcomes from its pivotal SEAL research analyzing ADAIR, Vallon’s anticipations with respect to the continued development of ADAIR and ADMIR, Vallon’s anticipations with regard to the vital strengths it believes its abuse-deterrent formulation of medication have more than very similar prescription drugs in the market place and the increasing have to have for abuse-deterrent formulations of medicine, Vallon’s capacity to employ the 505(b)(2) regulatory pathway, Vallon’s means to attain Fda acceptance of ADAIR and its other solution candidates, Vallon’s anticipations with respect to its funds runway and its capacity to attain cost reduction objectives. Ahead-seeking statements could be determined by the use of phrases this sort of as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the unfavorable of these words or other identical expressions. Even further, selected ahead-hunting statements are dependent on assumptions as to future functions that may perhaps not establish to be accurate. These and other dangers and uncertainties are explained a lot more absolutely in the segment titled “Risk Factors” in Vallon’s Quarterly and Yearly Reports submitted with the U.S. Securities and Exchange Fee. Ahead-looking statements contained in this announcement are manufactured as of this day, and the Firm undertakes no obligation to update this sort of data except as required under applicable regulation.

Investor Make contact with:
JTC Staff, LLC
Jenene Thomas
(833) 475-8247
[email protected]